<DOC>
	<DOCNO>NCT00634621</DOCNO>
	<brief_summary>The purpose study determine effectiveness hexaminolevulinate ( Hexvix ) diagnosis treatment patient non-invasive bladder cancer result change patient management .</brief_summary>
	<brief_title>Effectiveness Hexaminolevulinate ( Hexvix ) Diagnosis Treatment Patients With Non-invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Patients 18 year age . Patients either sex . Patients document highly suspect noninvasive bladder cancer . Patients hypersensitivity drug substance excipient Hexvix . Patients porphyry . Women childbearing age . Patients high risk suffer extensive bladder inflammation e.g . patient intravesical BCG treatment , patient moderate severe leukocyturia patient undergoing recent bladder surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Bladder</keyword>
	<keyword>Cancer</keyword>
	<keyword>Cystoscopy</keyword>
	<keyword>Hexaminolevulinate</keyword>
	<keyword>Hexvix</keyword>
</DOC>